Deals of the Week Watches Parkinson’s In Prime Time
This article was originally published in The Pink Sheet
Biogen Idec strikes a neurodegenerative research deal with Amicus Therapeutics and another antisense deal with Isis. Elsewhere, Merck and AstraZeneca team up in ovarian cancer, Roche obtains rights to two cancer immunotherapies from Inovio, and GSK sells a pair of beloved drinks to a Japanese beverage company.
You may also be interested in...
The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York